Anti-PARK7/DJ1 [malphaDJ-1/E2.19] antibody (ab11251)

Overview

  • Product nameAnti-PARK7/DJ1 [malphaDJ-1/E2.19] antibodySee all PARK7/DJ1 primary antibodies ...
  • Description
    Mouse monoclonal [malphaDJ-1/E2.19] to PARK7/DJ1
  • SpecificityThis clone has been shown to specifically recognise a fusion protein of PARK7/DJ1. It also recognises a FLAG-tagged PARK7/DJ1 expressed in eukaryotic cells. A single band is seen when Western blotting in optimised conditions with this clone. However, overloading the gel or using low dilutions can cause other bands to appear.
  • Tested applicationsFlow Cyt, IHC-Fr, ICC/IF, WB, ICC, IHC-FoFr more details
  • Species reactivity
    Reacts with: Human, Zebrafish

    Does not react with

    Mouse
  • Immunogen

    Recombinant full length protein (Human).

  • Positive control
    • In Flow Cytometry, this antibody gave a positive signal in HepG2 cells.

Properties

Applications

Our Abpromise guarantee covers the use of ab11251 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
Flow Cyt 1/100.
IHC-Fr Use at an assay dependent dilution.
ICC/IF 1/500.
WB Use at an assay dependent dilution. Detects a band of approximately 20 kDa.
ICC Use at an assay dependent dilution.
IHC-FoFr 1/1000.

Target

  • FunctionProtects cells against oxidative stress and cell death. Plays a role in regulating expression or stability of the mitochondrial uncoupling proteins SLC25A14 and SLC25A27 in dopaminergic neurons of the substantia nigra pars compacta and attenuates the oxidative stress induced by calcium entry into the neurons via L-type channels during pacemaking. Eliminates hydrogen peroxide and protects cells against hydrogen peroxide-induced cell death. May act as an atypical peroxiredoxin-like peroxidase that scavenges hydrogen peroxide. Following removal of a C-terminal peptide, displays protease activity and enhanced cytoprotective action against oxidative stress-induced apoptosis. Stabilizes NFE2L2 by preventing its association with KEAP1 and its subsequent ubiquitination. Binds to OTUD7B and inhibits its deubiquitinating activity. Enhances RELA nuclear translocation. Binds to a number of mRNAs containing multiple copies of GG or CC motifs and partially inhibits their translation but dissociates following oxidative stress. Required for correct mitochondrial morphology and function and for autophagy of dysfunctional mitochondria. Regulates astrocyte inflammatory responses. Acts as a positive regulator of androgen receptor-dependent transcription. Prevents aggregation of SNCA. Plays a role in fertilization. Has no proteolytic activity. Has cell-growth promoting activity and transforming activity. May function as a redox-sensitive chaperone.
  • Tissue specificityHighly expressed in pancreas, kidney, skeletal muscle, liver, testis and heart. Detected at slightly lower levels in placenta and brain. Detected in astrocytes, Sertoli cells, spermatogonia, spermatids and spermatozoa.
  • Involvement in diseaseDefects in PARK7 are the cause of Parkinson disease type 7 (PARK7) [MIM:606324]. A neurodegenerative disorder characterized by resting tremor, postural tremor, bradykinesia, muscular rigidity, anxiety and psychotic episodes. PARK7 has onset before 40 years, slow progression and initial good response to levodopa. Some patients may show traits reminiscent of amyotrophic lateral sclerosis-parkinsonism/dementia complex (Guam disease).
  • Sequence similaritiesBelongs to the peptidase C56 family.
  • Post-translational
    modifications
    Sumoylated on Lys-130 by PIAS2 or PIAS4; which is enhanced after ultraviolet irradiation and essential for cell-growth promoting activity and transforming activity.
    Cys-106 is easily oxidized to sulfinic acid.
    Undergoes cleavage of a C-terminal peptide and subsequent activation of protease activity in response to oxidative stress.
  • Cellular localizationCytoplasm. Nucleus. Mitochondrion. Under normal conditions, located predominantly in the cytoplasm and, to a lesser extent, in the nucleus and mitochondrion. Translocates to the mitochondrion and subsequently to the nucleus in response to oxidative stress and exerts an increased cytoprotective effect against oxidative damage. Detected in tau inclusions in brains from neurodegenerative disease patients.
  • Target information above from: UniProt accession Q99497 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
  • Alternative names
    • CAP1 antibody
    • DJ 1 antibody
    • DJ-1 antibody
    • DJ1 antibody
    • DJ1 protein antibody
    • DJ1 protein antibody
    • FLJ27376 antibody
    • FLJ34360 antibody
    • FLJ92274 antibody
    • Oncogene DJ1 antibody
    • OTTHUMP00000001348 antibody
    • OTTHUMP00000001349 antibody
    • OTTHUMP00000001350 antibody
    • OTTHUMP00000001351 antibody
    • Park 7 antibody
    • Park7 antibody
    • PARK7_HUMAN antibody
    • Parkinson disease (autosomal recessive early onset) 7 antibody
    • Parkinson disease (autosomal recessive, early onset) 7 antibody
    • Parkinson disease protein 7 antibody
    • Parkinson protein 7 antibody
    • Protein DJ 1 antibody
    • Protein DJ-1 antibody
    • RNA binding protein regulatory subunit antibody
    • RS antibody
    • SP22 antibody
    see all

Anti-PARK7/DJ1 [malphaDJ-1/E2.19] antibody images

  • Western blot using clone malphaDJ-1/E2.19 and a beta actin antibody as a loading control.

    The bottom band is PARK7/DJ1, the top band is beta actin.

    Lane 1: 293 cell lysate

    Lane 2: MCF-7 cell lysate

    Lanes 3-7: various different prostate cell lines

    Lane 8: recombinant PARK7/DJ1 (that was used as immunogen for this antibody)

  • Western blot using ab11251 at 1/500 on HeLa whole cell lysate (20µg/lane).
  • ICC/IF image of ab11251 stained human HeLa cells. The cells were PFA fixed (10 min), permabilised in TBS-T (20 min) and incubated with the antibody (ab11251, 1:500 dilution) for 1h at room temperature. 1%BSA / 10% normal goat serum / 0.3M glycine was used to quench autofluorescence and block non-specific protein-protein interactions. The secondary antibody (green) was Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red). DAPI was used to stain the cell nuclei (blue).
  • Overlay histogram showing HepG2 cells stained with ab11251 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab11251, 1/100 dilution) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgM [ICIGM] (ab91545, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in HepG2 cells fixed with 4% paraformaldehyde (10 min)/permeabilized with 0.1% PBS-Tween for 20 min used under the same conditions.

References for Anti-PARK7/DJ1 [malphaDJ-1/E2.19] antibody (ab11251)

This product has been referenced in:
  • Principe S  et al. Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine. J Proteome Res 11:2386-96 (2012). WB . Read more (PubMed: 22339264) »
  • Kim Y  et al. Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. Mol Cell Proteomics 11:1870-84 (2012). WB . Read more (PubMed: 22986220) »

See all 7 Publications for this product

Product Wall

Thank you for your enquiry.

I have investigated our records for ab11251. I am sorry toconfirm there is an error on the datsheet and that this antibody is sold as ascites. The datasheet has been updated with the correct information and I apol...

Read More

Thank you for contacting us and reporting the problems you have encountered with ab11251. Unfortunately xxx is away today but she has asked me to get in contact with you.

xxxxhas been investigating how the antibody is produced and purified in...

Read More
Application Western blot
Sample Human Cell lysate - whole cell (normal fibroblasts)
Loading amount 40 µg
Specification normal fibroblasts
Gel Running Conditions Reduced Denaturing (12 % polyacrylamide gel)
Blocking step BSA as blocking agent for 12 hour(s) and 0 minute(s) · Concentration: 1% · Temperature: 22°C
Username

Dr. Paule Benit

Verified customer

Submitted May 03 2010

Application Immunocytochemistry/ Immunofluorescence
Sample Human Cell (normal human fibroblasts)
Specification normal human fibroblasts
Fixative Formaldehyde
Permeabilization Yes - 1X PBS 0.25% Triton
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 1% · Temperature: 37°C
Username

Dr. Paule Benit

Verified customer

Submitted Apr 23 2010

Thank you for your enquiry. Ab11251 has been tested for application in Western blotting and Immunocytochemistry, and has not yet been tested in any other applications (including IP). For Western blotting, I would recommend starting at a dilution of 1:5...

Read More

Thank you very much for your enquiry and for your patience. Ab11251 was originated outside Abcam and according to the originator, they had positive feedback from a researcher who found the antibody to cross-react with zebrafish. That is unfortunately a...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"